Talk:Parexel

Proposed "Acquisition history" updates

My name is Danaka Williams and I work for Parexel in the Corporate Communications department. The current "Acquisition history" section relies heavily on citations to Parexel itself, is incomplete, and has a few other issues. I'd like to propose replacing it with a table, similar to what is commonly used on other pages[1][2]. Below is the proposed table that includes every acquisition with independent citations available. Pursuant to WP:COI, I'm asking for an impartial editor to consider whether it would be an incremental improvement to replace the bulleted list with the below table.

New acquisitions section

	Date	Company	Business	Location	Value (USD)	Ref(s).
1	1988	Consulting Statisticians	Data and statistics firm	Boston, MA
2	1989	Clinical Trial Analysis division of McDonnell Douglas Corporation	Biostatistics and analysis
3	1990	Barnett Associates	Training, education, logistics support, and IT systems	Philadelphia, Pennsylvania
4	1991	Arzneimittelforschung GmbH	Phase I-IV clinical trials	Germany
5	1996	Sitebase Clinical Systems	Data entry and management	Massachusetts
6	1996	Caspard Consultants	Monitoring and analysis	France
7	1996	Washington State and Federal Associates Inc.	Marketing and sales	Washington, USA
8	1996	Lansal Clinical Pharmaceuticals	Clinical trials, phase I-IV	Tel-Aviv
9		Rescon Inc.	Marketing	United States
10		Perceptive Systems Inc.	Imaging software	United States
11		Kemper-Masterson	Validation and compliance consulting	Boston, MA
12	1998	PPS Europe Ltd	Pharmaceutical marketing	United Kingdom	2.9 million shares
13	1998	Logos GmbH	Regulatory consulting	Germany	100,000 shares
14	1998	Mirai BV	Contract Research Organization	Netherlands	675,000 shares
15	circa 2000	Farmovs	Contract Research Organization	South Africa
16	circa 2000	CEMAF	Clinical research facility	France
17	2001	EDYABE	Contract research	Latin America
18	2002	PW Pharma Systems	Clinical trial management software	United Kingdom	$15.4 million
19	2002	Pracon & Health IQ	Medical marketing	United States
20	2004	3ClinicalResearch AG	Phase I and proof-of-concept clinical trials	Germany	$12 million
21	2004	Integrated Marketing Concepts	Call center for recruiting patients, support, market research, and sales	United States
22	2005	QdotPharma	Phase I and II clinical trials	South Africa	$6 million
23	2006	Behavioral and Medical Research + California Clinical Trials Medical Group	Phase I-IV clinical trials	California, USA	$65 million
24	2007	Apex International Clinical Research Co. Ltd. (minority interest)	Contract Research Organization	Taiwan	$50.9 million
25	2008	ClinPhone	Clinical trial automation and management technology	United Kingdom	$177 million
26	2013	Heron Group	Economics consulting	United Kingdom	$38.2 million
27	2012	Liquent	Medical and research software	United States	$72 million
28	2014	ATLAS Medical Services	Clinical research	Turkey
29	2014	ClinIntel	Randomization and trial supply management	United Kingdom
30	2024	Quantum Solutions	Pharmacovigilance	India
31	2016	ExecuPharm Holding Company	Clinical research services	United States
32	2017	The Medical Affairs Company	Medical marketing firm	United States
33	2016	Health Advances	Consulting services	United States
34	2017	Anolinx	Epidemiology and informatics
35	2020	Model Answers	Pharmacokinetic modeling and consulting	Australia
36	2020	Roam Analytics	Natural Language Processing	United States

References

DWwilliams001 (talk) 17:36, 17 December 2024 (UTC)

So, COI-wise this seems basically unobjectionable to me. As a matter of article quality, this doesn't really feel much better? I mean, it also doesn't feel much worse, giant lists of acquisitions kind of suck regardless of the format, but I don't really see the point of this. Ideally it this would look something like a "History" section with important acquisitions woven in with other important events, but I understand that the goal here was incremental improvement rather than a massive overhaul. Leaving this for someone else to formally review, but that's my two cents Rusalkii (talk) 06:49, 24 January 2025 (UTC)

@Rusalkii: It is a fairly administrative type of improvement to replace primary sources and improve the formatting. I think the reason these M&A tables are so prolific on Wikipedia[3][4][5][6] is because listing 36 acquisitions in paragraph form would be very monotonous when there are a large number of acquisitions.

We can make some variability from sentence to sentence, but essentially a paragraph format would read "In YEAR, acquired BUSINESS for MONEY" 36 times sprinkled throughout the historical narrative. I can rework it into paragraph format if editors prefer though. I just started on the M&A list because it seemed like something fairly straightforward. DWwilliams001 (talk) 21:18, 18 February 2025 (UTC)

I mean, I think if there's nothing to say other than "In Year they acquired Company" x36 then most of those mergers and acquisitions simply shouldn't be mentioned.

This isn't a denial of the request, to be clear, as I said COIwise this doesn't really affect anything, but my personal take on the matter. Rusalkii (talk) 21:38, 18 February 2025 (UTC)

@Rusalkii:, If it hasn't been taken notice by an independent news outlet in the form that isn't churnalism, I think it ought not be mentioned. Wikipedia articles shouldn't be a corporate second front "About us" page. Graywalls (talk) 22:02, 12 March 2025 (UTC)

History expansion

Thanks so much @Zefr: etc. for cleaning up the page and reviewing the early history content I proposed. Below is the rest of the content I'd like to propose be added to the end of the current History section to continue filling it out with encyclopedic content. This draft omits the acquisition table and the TGN1412 controversy merely in order to conform to the feedback of impartial editors here on Talk and is not intended to censor the controversy via omission.

Rest of History section

IPO & acquisitions

Parexel went public on NASDAQ in 1995. It used the funding to make a series of acquisitions, including six consulting companies, two medical marketing businesses, and three European businesses in 1998. Parexel acquired an average of more than one business per-year. By 2018, Parexel had completed more than 40 mergers and acquisitions. In 1998, Parexel created a new business unit focused on technology, which was spun-off as Perceptive Informatics in 2000. The company grew to $60 million in revenues by 1995 and $350 million by 1999.

Recent history

In 1999, Covance and Parexel planned a merger that involved a $526 million purchase by Covance and combining the two company names. However, the merger was called off in 2000. Parexel had two rounds of layoffs that year, reducing its workforce by about 10 percent, due to an overall decline in their industry. Parexel then rebounded the following year. In 2004, Parexel started a partnership with contract research organization Synchron Research Services. Later that year, the two companies formed a joint venture, whereby Parexel acquired Synchron's clinical trials business in Bangalore, India and a minority interest in Synchron's pharmacology business.

In September 2017, private equity firm Pamplona Capital Management bought Parexel for $5 billion, taking it off the public market. By this time, Parexel had more than $2 billion in annual revenues. That year, co-founder and CEO Josef von Rickenbach retired. Jamie Macdonald was appointed as the new CEO. In 2021 Parexel was acquired again for $8.5 billion by two private equity firms, EQT Private Equity and Goldman Sachs Asset Management. In 2024, Jamie Macdonald retired and former COO and Chief Growth Officer Peyton Howell was appointed as the new CEO.

References

As before, let me know if I can be of any further assistance or if you need PDFs of any citations not available online. DWwilliams001 (talk) 20:13, 19 March 2025 (UTC)

With Special:Diff/1281346958, I implemented part of your request, excluding some as having only minor importance, WP:UNDUE. Zefr (talk) 20:50, 19 March 2025 (UTC)

Operations section

I would like to propose the Operations section be replaced with something more closely resembling the following draft:

Draft

Parexel is a contract research organization that supports pharmaceutical companies with clinical trials, regulations, and marketing. It also represents clients before the U.S. Food and Drug Administration and similar regulatory bodies. The company designs clinical trials, provides consulting on marketing and regulations, then manages and analyzes the data resulting from the clinical trial.

Parexel Consulting focuses on consulting on issues like manufacturing, regulations, and development. It was introduced in 2002. A real-world data (RWD) service attempts to calculate the economic value of new medicines and is often used to justify expensive medicines to health insurance companies. After the COVID-19 pandemic, the company shifted a lot of its clinical trial operations to a more remote-centric model.

References

References

The following explains each change between what's up now and this draft and why the change is proposed:

Changes

1. Trims the reference to 21,000 employees which is duplicative of the infobox
2. Trims the long list of fields Parexel works in. A complete list would be double the length and violates WP:NOTDIRECTORY)
3. Trims the reference to a partnership with Palantir Technologies (could be moved to history but the citation is a short blurb)
4. Replaces the trimmed content with more information and context about Parexel's operations, such as representing companies before the FDA, analytics, manufacturing, and the shift to remote clinical trials after COVID.

Also, since the History section is smaller than the proposed, I suggest it be consolidated so that all of the content is under just one "History" section without dividing it into sub-sections that are just one paragraph long. Pinging @Zefr: who has been helping out with prior requests. DWwilliams001 (talk) 15:04, 1 April 2025 (UTC)

Respectfully, having reviewed your suggestions and sources, I don't feel the article is improved by the recommended changes. 1) the Operations section adequately summarizes what the company does as a broad-service CRO. 2) the sources you suggested are all out-of-date by many years, do not have accessible URLs, and do not provide updated information from either the 2025 company website or the most recent 2021 MedCity News source. 3) under Operations, I think the Palantir collaboration is significant, as it introduces an AI leader into Parexel's business. Of note, Palantir's market cap is about 12 times more valuable than Parexel's 2021 acquisition of $8.5 billion.

Other editors can evaluate your suggestions and revise accordingly. I don't see anything further to add or change at this point. Zefr (talk) 17:01, 1 April 2025 (UTC)